文献速递肝病

北美慢性乙型肝炎队列中肝脂肪变与脂肪性肝炎研究

Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

该研究纳入420例未抗病毒治疗的北美慢性HBV成人,经肝活检评估脂肪肝病变。31.4%存在脂肪肝,13.1%为脂肪性肝炎;脂肪性肝炎与基线进展期纤维化风险升高1.68倍相关,并与4年内ALT和FIB-4持续升高独立相关。

要点

  • 慢性HBV成人中约三分之一合并脂肪肝,13.1%为脂肪性肝炎。
  • 脂肪性肝炎与基线进展期纤维化风险升高1.68倍相关。
  • 脂肪性肝炎独立关联4年内ALT升高1.39倍和FIB-4升高1.25倍。

核心结论

  • 在北美慢性HBV成人队列中,脂肪性肝炎与进展期纤维化及随访期间肝酶和纤维化指标升高相关,提示除抗病毒外需筛查和管理代谢异常。

研究设计与样本

  • 研究纳入420例未接受HBV治疗的乙肝表面抗原阳性成人,经肝活检评估炎症和纤维化。
  • 脂肪性肝炎定义基于脂肪变、肝细胞气球样变±Mallory-Denk小体及窦周纤维化。

主要发现

  • 年龄较大、超重/肥胖和糖尿病与脂肪性肝炎相关。
  • 脂肪性肝炎 vs 无脂肪肝与基线进展期纤维化风险升高1.68倍相关(95%CI 1.12-2.51)。
  • 脂肪性肝炎 vs 无脂肪肝独立关联4年内平均ALT升高1.39倍(P<0.01)和FIB-4升高1.25倍(P=0.04)。

临床怎么用

  • 对慢性HBV患者应筛查代谢异常(超重/肥胖、糖尿病)并管理,以预防疾病进展。

局限性

  • 研究为横断面肝活检队列,随访中肝硬化发生率仅有提示性升高,未明确证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Fatty liver disease (FLD) influences liver disease progression and liver cancer risk. We investigated the impact of FLD on liver disease severity in a large North American cohort with chronic hepatitis B virus (HBV). METHODS: Liver biopsies from 420 hepatitis B surface antigen-positive adults enrolled in the Hepatitis B Research Network and who were not on HBV therapy in the previous month were evaluated for inflammation and fibrosis. Steatohepatitis was based on steatosis, hepatocyte ballooning ± Mallory-Denk bodies, and perisinusoidal fibrosis. Models evaluated factors associated with steatohepatitis, and the associations of steatohepatitis with fibrosis, and longitudinal alanine aminotransferase, aspartate aminotransferase, and Fibrosis-4. RESULTS: The median age was 42 years, 62.5% were male, and 79.5% were Asian. One hundred thirty-two (31.4%) patients had FLD (77 [18.3%] steatosis only, 55 [13.1%] steatohepatitis). Older age, overweight/obesity, and diabetes were associated with steatohepatitis. Steatohepatitis (vs no FLD) was associated with 1.68 times higher risk of advanced fibrosis at baseline (95% confidence interval, 1.12-2.51), and there was an indication of higher incident cirrhosis rate during follow-up. Steatohepatitis vs no FLD was also independently associated with, on average, 1.39 times higher alanine aminotransferase (P < 0.01) and 1.25 times higher Fibrosis-4 (P = 0.04) across 4 years. DISCUSSION: Coexisting steatosis occurred in nearly a third of adults (13% had steatohepatitis) with chronic HBV in this North American cohort who underwent liver biopsies. Steatohepatitis was associated with advanced fibrosis and higher biochemical measures of hepatic inflammation over time. Therefore, in addition to viral suppression, screening for and managing metabolic abnormalities is important to prevent disease progression in HBV.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Khalili M, Kleiner DE, King WC, et al. Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B. Am J Gastroenterol. 2021. PMID: 33840726. doi:10.14309/ajg.0000000000001257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。